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Summary. Ischemic heart disease is a widespread cause
of death. During infarction, myocardial injury is
mediated by release of several pro-inflammatory
cytokines including multifunctional interleukin-1 (IL-1).
In various tissues, IL-1-mediated deleterious effects are
known to be attenuated via the over-expression of
natural anti-inflammatory cytokine IL-1 receptor
antagonist (IL-1ra). In the present investigation, IL-1ra
distribution in healthy and infarcted myocardium was
studied by light and electron microscopy. After
immunostaining, weak positivity resulted for
cardiomyocytes in normal myocardium and, at higher
degrees, in infarction border areas and ischemic ones. In
ischemic areas, additional reactivity was displayed by
the extracellular matrix and intravascular plasma.
Immunogold labelling provided further details on
intracytoplasmatic and extracellular distribution; in
particular, noticeable gold particle distribution appeared
on intercalated discs in normal and hypertrophic
cardiomyocytes, as well as on thickened Z-lines for
these latter. The present results suggest that
cardiomyocytes represent a major source of IL-1ra in
vivo, even though additional contribution by blood
derived IL-1ra is to be taken in account in ischemic
areas. In addition, ischemia-associated intracytoplasmic
IL-1ra increase and its additional presence in the
extracellular matrix is consistent with the concept that
this cytokine plays a cardioprotective role at different
levels and by distinct mechanisms. 
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Introduction
Among the members of Interleukin family,
interleukin-1 (IL-1) consists of two agonists, IL-1α and
IL-1ß, and a specific receptor antagonist, IL-1ra, each
acting as a ligand for two receptors termed IL-1R type I
and IL-1R type II (Arend et al., 1998). The molecule
now known as IL-1ra was originally referred as an IL-1
inhibitor in the supernatants of human monocytes
cultured on adherent IgG (Arend et al., 1985). Then, this
first isoform of IL-1ra was also reported to be secreted
from macrophages, neutrophils, hepatocytes, endothelial
cells and microglial cells and is now termed sIL-1ra
(Arend et al., 1998). Besides the secreted isoform, three
additional IL-1ra intracellular isoforms have been
described to date. One of these, termed icIL-1ra1, was
originally found in epithelial cells (Haskill et al., 1991)
and subsequently in monocytes, macrophages,
fibroblasts, and endothelial cells (Arend and Guthridge,
2000). A cDNA coding for a second intracellular
isoform, termed icIL-1ra2, was cloned from human
leukocytes (Muzio et al., 1995), even though this
predicted protein was never found to be expressed in
vivo. 
The third isoform, termed icIL-1ra3, was mainly
found to be expressed in neutrophils and hepatocytes
(Malyak et al., 1998) and is also detectable in smaller
amounts in monocytes, macrophages, and epithelial cells
(Arend and Guthridge, 2000).
IL-1 isoforms are reported to play a key role in the
complex cytokine network, regulating important
functions during development, cell differentiation, tissue
remodelling, infection, inflammation and cell death
(Loppnow et al., 2001; Arend, 2002). On the other hand,
IL-1ra detection in patients with inflammation, infection,
allergic disease, cancer and various postoperative
conditions is consistent with its involvement in
mediating anti-inflammatory responses in a wide variety
of anatomical districts such as joints (Firestein et al.,
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1992; Arend and Gabay, 2000), gastrointestinal tract
(Sekiyama et al., 1994; Casini-Raggi et al., 1995; Daig
et al., 2000; Mayer et al., 2000), lung (Mikuniya et al.,
2000; Hagaman et al., 2001), kidney (Pereira et al.,
1994; Tam et al., 1994) and central nervous system
(Loddick et al., 1997; Wong et al., 1997; Allan, 1998).
Thus, IL-1ra seems competitively to block IL-1 agonistic
isoforms binding to cell surface receptors, regulating
their multifunctional effects in various tissues (Arend et
al., 1998; Arend and Guthridge, 2000; Arend, 2002). 
Since IL-1ra can be virtually expressed by any IL-1-
producing cell, it is likely that correct balance between
IL-1 and IL-1ra in local tissues is crucial for the
maintenance of physiologic conditions, whereas
imbalance between these cytokines can lead to
pathological disorders (Arend and Guthridge, 2000;
Arend, 2002). There are many evidences supporting the
concept that perturbations of IL-1/IL-1ra ratio are
involved in the pathogenesis of several cardiovascular
tissue diseases (Loppnow et al., 2001). Particularly,
elevated amounts of IL-1 isoforms have been detected in
human atherosclerotic arterial wall (Tipping and
Hancock, 1993; Galea et al., 1996) and in hearts from
patients affected by dilated cardiomyopathy (Francis et
al., 1998; Ukimura et al., 2003) and ischemic disease
(Oyama et al., 2001; Pomerantz et al., 2001). 
Elevated levels of IL-1 isoforms were also detected
in sera from patients affected by myocarditis (Matsumori
et al., 1994; Abe et al., 2004) or myocardial infarction
(Guillen et al., 1995; Balbay et al., 2001). 
Further, it has been reported that cardiomyocytes can
produce IL-1 in vitro in response to injury (Müller-
Werdan et al., 1998). Likewise, IL-1ra was reported to
be involved in atherosclerosis (Dewberry et al., 2000),
chronic congestive heart failure (Missov et al., 1997),
and myocarditis (Abe et al., 2004). Moreover, elevated
IL-1ra serum levels were found in patients with acute
myocardial infarction (Latini et al., 1994; Shibata et al.,
1997; Patti et al., 2004). However, it remains unclear
which is/are actual source/s for IL-1ra in human
infarcted myocardium.
Several studies evidenced that apoptosis is involved
in the pathogenesis of various cardiovascular diseases
(Saraste et al., 1997; Yaoita et al., 2000; Akasaka et al.,
2006). Moreover, possible correlation between apoptosis
and IL-1 family cytokines has been reported.
Particularly, animal models of ischemia-reperfusion
(I/R) injury were used to demonstrate that induced over-
expression of IL-1ra (Suzuki et al., 2001) or selective
inhibition of IL-1 (Yaoita et al., 1998) caused a reduction
of infarct size, inflammatory response and IL-1-
mediated apoptosis, preventing ischemia-induced
myocardial dysfunction.
The present study focuses on the expression of IL-
1ra in human healty and infarcted myocardium and the
obtained results strongly suggest that the major source of
IL-1ra in vivo is represented by cardiomyocytes
supporting the concept that this cytokine plays a




Human myocardium samples were excised from (i)
nonischemic areas, (ii) border areas, and (iii) ischemic
areas of eight hearts explanted from cardiac transplant
recipients secondary to myocardial infarction (n=8; 6
males and 2 females; mean age was 52 years).
Additional samples were excised from two autoptic
hearts from noninfarcted patients (n=2; 1 male and 1
female; mean age was 56 years). 
After fixation with 4% neutral buffered
paraformaldehyde, the samples were reduced and
grouped into lot 1, for light microscopy processing, and
lot 2, for electron microscopy processing. Samples of lot
1 were routinely dehydrated and embedded in paraffin.
Serial sections were cut at 5µm thickness and mounted
on poly-L-lysine precoated slides. Histological sections
were stained with picro-Sirius red and hematoxylin or
subjected to immunohistochemical reactions. Samples of
lot 2 were dehydrated in graded ethanols and embedded
in LR-White resin. Semithin sections were stained with
1% toluidine blue in aqueous solution. Ultrathin sections
were collected on nickel grids and subjected to
immunogold labelling reactions.
Immunohistochemical detection of IL-1ra
Deparaffinized and rehydrated histological sections
from lot 1 samples were incubated for 10 min in 0.1%
Triton X-100 solution to improve membrane
permeability; endogenous peroxidase activity was
inhibited by 5 min incubation in 3% H2O2; masking of
non-specific binding sites was performed by incubation
in 3% normal donkey serum for 30 min. Subsequently,
sections were incubated with goat anti-human 1:25
diluted IL-1ra polyclonal antibody (Santa Cruz Biotech.
Inc., CA, USA), for 2h, and finally with peroxidase-
conjugated donkey anti-goat secondary antibody for 1 h
at room temperature. Peroxidase activity was revealed
by incubation with diaminobenzidine tetrahydrochloride
(DAB) and H2O2 (Vector Lab. Inc., CA, USA). After
washing, sections were weakly counterstained with
hematoxylin. As negative control, primary antibody was
replaced by donkey serum. Specificity of primary
antibody had been previously assessed on human skin
histological sections subjected to immunohistochemical
reactions as above. Observations and photographic
records were made using a Reichert-Jung Polyvar light
microscope.
Immunogold labelling detection of IL-ra
Ultrathin sections from lot 2 samples were incubated
for 10 min in 0.05M TRIS-HCl buffer, pH 7.6, added
with 0.1% BSA. After incubation with 5% normal
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donkey serum for 30 min, ultrathin sections were
incubated with goat anti-human 1:25 diluted IL-1ra
polyclonal antibody, overnight at 4°C. After washing
with the same buffer, ultrathin sections were incubated
with biotinylated donkey anti-goat secondary antibody
(Amersham Ltd, Buckinghamshire, UK), for 1h.
Subsequently, ultrathin sections were incubated with
0.02M TRIS-HCl buffer, pH 8.2, added with 0.1% BSA,
for 10 min, and finally with 10nm gold-conjugated
streptavidin (Amersham Ltd, Buckinghamshire, UK), for
1h. After washing, sections were weakly contrasted with
uranyl acetate and lead citrate. As negative control,
primary and/or biotinylated secondary antibodies were
omitted during sample processing. Specificity of primary
antibody had been previously assessed on human skin
ultrathin sections subjected to immunogold labelling as
above. Observations and micrographic records were




In normal heart samples, myocardium displayed
weak IL-1ra immunoreactivity at level of
cardiomyocytes, whereas the cytokine was not present in
the interstitium (Fig. 1A). 
Concerning infarcted heart samples, nonischemic
myocardium areas exhibited positivity patterns
comparable with those in normal myocardium, except
for little more marked reactivity exhibited by myocytes
(Figs. 1B,C, 2B).
In the border zone of the infarction, cardiomyocytes
showing coagulation necrosis to early coagulative
myocytolysis features were characterized by increased
positivity for IL-1ra. The extracellular matrix was
generally negative or weakly positive in places (Figs.
1D,E, 2B).
After picro-Sirius red staining, samples from
ischemic zones showed areas occupied by
ipervascularized dense connective tissue, as well as areas
where pale, small cardiac muscle cells affected by
prominent loss of cytoplasmatic substance and
intercellular contacts were interspersed within abundant
extracellular matrix (Fig. 2A). In addition to such
damages correlating with advanced coagulative
myocytolysis, these cardiomyocytes also disclosed
strong reactivity for IL-1ra (Figs. 2B, 1F,G). Moreover,
remarkable immunoreactivity was apparent for the
extracellular matrix and few interstitial cells likely
corresponding to neutrophils and macrophages (Figs.
1F-H, 2B). Interestingly, connective tissue immuno-
reactivity was more evident near blood vessels and
cardiomyocytes. Conversely, no immunoreactivity was
detected for vascular smooth muscle cells (Fig. 1F) and
endothelial cells (Fig. 1D,F,H), even though IL-1ra
antibody stained residual plasma in blood vessel lumens
in the ischemic areas (Fig. 1F,H).
Electron microscopy
On ultrathin sections, immunogold labelling
reactions for IL-1ra were consistent with the distribution
patterns displayed by light microscopy. 
In normal heart samples, weak reactivity for IL-1ra
was restricted to cardiomyocytes, in which a moderate
gold particle distribution was apparent with preferential
localization at level of the intercalated discs (Fig. 3A),
whereas no IL-1ra-immunopositivity was shown by
noncardiac cells and extracellular matrix.
In infarcted heart samples excised from non-
ischemic areas, similar labelling was observed as above
(Fig. 3B), except for a slightly increased presence of
metal particles on the muscular fibers and intercalated
discs, with addition of Z-lines as preferential labelling
sites, even if barely perceivable.
In samples excised from both border zones and
ischemic areas of the infarction, remarkable intracellular
immunoreactivity for IL-1ra was shown by injured
cardiomyocytes. 
In cardiomyocytes seemingly involved in initial
coagulation necrosis, gold particles were particularly
abundant at level of thickened Z-lines (Fig. 3C) and
intercalated discs (Figs. 3C,D), which were often
characterized by multiple, overgrown interdigitations
(Fig. 3D).
Additionally, gold particles decorated
plasmamembrane tracts as well as degenerating
mitochondria and heterogeneous, rounded organule
remnants resulting from coagulative myocytolysis
progression in cardiomyocytes (Fig. 4A).
In ischemic areas, immunoreactivity for IL-1ra was
still present in cardiomyocytes which resembled cell
“ghosts” because of dramatic loss of the contractile
component depending on protracted myocytolysis (Fig.
4B-D). Moreover, in the extracellular matrix, gold
particles were mainly localized at correspondence with
collagen fibrils, elastin fibres and fibrillin microfibrils
(Fig. 4A-D). IL-1ra-immunoreactive extracellular matrix
components were mainly found near cardiomyocytes and
blood vessels.
Discussion
The involvement of IL-1ra in myocardial infarction
and its beneficial role in limiting IL-1-mediated cardiac
dysfunction have been shown to occur in several animal
models of I/R injury (Suzuki et al., 2001; Chimenti et al.,
2004). However, experimental conditions show some
limitations. First, some unavoidable differences will
exist between the effects of induced I/R injury in animal
models and what actually happens in naturally occurred
myocardial infarction in humans. Second, IL-1ra
abundance depends on experimental administration in
animal models, thus unabling to determine which is/are
the effective source/s of IL-1ra in organs and tissues.
IL-1ra involvement in counteracting IL-1-mediated







IL-1ra in normal and
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A. Myocardium sample
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C. Nonischemic
myocardium samples




























matrix. A, B, D-G, x 20;
C, H, x 8
myocardial infarction because of the assessment of
raised plasmatic IL-1ra levels in patients undergone
ischemic episodes (Latini et al., 1994; Shibata et al.,
1997; Patti et al., 2004). In a first attempt to explain this
phenomenon, it has been suggested that circulating IL-
1ra may act as an acute phase protein secreted by
hepatocytes (Gabay et al., 1997). Despite IL-1ra was
subsequently reported to be a natural anti-inflammatory
protein produced by many other cells (Arend et al.,
1998; Arend, 2002), such an involvement was still
unexplored for cardiomyocytes. In this study, therefore,
the possibility was investigated that myocardium could
be a source of IL-1ra, and the first evidence that
noninfarcted cardiomyocytes constitutively produce IL-
1ra has been achieved. Since IL-1ra seems to balance the
IL-1-mediated effects not only in pathological conditions
but also in physiologic ones (Arend, 2002), it is likely
that basal production of IL-1ra can normally occur in
healthy cardiomyocytes. Moreover, IL-1ra production
resulted to undergo a significant increase during
myocardial infarction, being IL-1ra immunoreactivity
progressively more intense moving from nonischemic
toward ischemic areas of infarcted myocardium. 
In particular, the main source of IL-1ra was
identified in cardiomyocytes affected by either
coagulation necrosis or coagulative myocytolysis in the
ischemic and border areas of infarction, whereas only
faint IL-1ra-positivity was detected for cardiomyocytes
populating the nonischemic areas. 
Taking in account that apoptotic cell death occurs in
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Fig. 2. Low magnification of a human infarcted heart sample showing myocardial nonischemic (n), ischemic (i), and border zones (b). A. Picro-Sirius
red and hematoxylin staining. B. Immunohistochemical reaction with goat anti-human IL-1ra polyclonal antibody and counterstaining with hematoxylin.
x 3
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Fig. 3. Immunogold labelling with anti-IL-1ra Ab in normal and infarcted heart samples. A. Myocardium sample from normal heart: preferential
distribution of gold particles on an intercalated disc. B. Myocardium sample from a non-ischemic zone of infarcted heart: as for (A), with slightly higher
gold particle distribution. C, D. Myocardium samples from ischemic zones of infarcted heart: generalized increase in gold particle distribution with
preferential propensivity exhibited by thickened Z-lines (C) and multiple intercalated discs (C, D). A, D, x 11,000; B, x 8,500; C, x 10,400.
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Fig. 4. Immunogold labelling with anti-IL-1ra Ab in infarcted heart samples. A. Gold particles on dense body-like structures and degenerating
mitochondria in ischemic cardiomyocytes. Gold particles on extracellular matrix components (fibrillin microfibrils (f)). B-D. Gold particles on
cardiomyocyte ghosts (CG). Gold particles on extracellular matrix components, collagen fibrils (c), elastic fibers (e) and fibrillin microfibrils (f). (F:
fibroblast). A-C, x 18,500; D, x 14,000.
acute myocardial infarction (Saraste et al., 1997; Yaoita
et al., 2000; Akasaka et al., 2006) and that IL-1
expression correlates with apoptosis (Yaoita et al., 1998),
it is likely that the observed IL-1ra production increase
can be ascribed to an attempt by cardiomyocytes to
contrast IL-1-induced apoptosis.
In ischemic myocardium, cardiomyocytes are known
to be characterized by features comparable with those in
cardiac hypertrophy, such as formation of multiple
intercalated discs, Z-line thickening, and degenerative
changes including loss of contractile elements and
intercellular connections (Maron and Ferrans, 1978). 
In the present work, the observed ultrastructural
damage features, such as thickened Z-lines and
intercalated discs showing multiple, overgrown
interdigitations, are consistent with those previously
reported for ischemic myocardium. Additional
information is represented by the relation found between
the onset and progression of cardiomyocyte alterations
and progressive increasing in immunogold labelling for
IL-1ra. Putatively, the increased propensity to this
immuno-labelling by multiple intercalated discs and
thickened Z-lines might indicate that this protein plays
some protective role for cardiomyocytes undergoing
hypertrophic processes. 
Since these two sites are coincevably subjected to
the strongest mechanical forces, it could be speculated
that one of the ways by which IL-1ra exerts its cardio-
protective ability consists in a stabilizing role as regards
the connection between contractile apparatus and
intercalated discs and costameric machinery.
Consistently, in cardiomyocytes the costameric protein
complexes involved in mechanotransduction between
cytoplasmic contractile filaments and extracellular
matrix components closely interact with the outer Z-
lines (Danowsky et al., 1992; Samarel, 2005).
Interestingly, some evidences suggest the existence
of other relationship between IL-1ra and myofilament
rearrangement in skeletal muscle. In particular, in animal
models of sepsis it has been reported that infusion of IL-
1ra can prevent infection-induced inhibition of
myofilament protein synthesis (Zamir et al., 1994; Vary
et al., 1996).
Despite the antibody used in this study could not
discriminate between IL-1ra secreted isoform and
intracellular ones, it is likely that cytoplasmic IL-1ra
revealed in normal and nonischemic cardiomyocytes
corresponds to an intracellular isoform since no
immunoreactivity was detected at level of endoplasmic
reticulum or secretory vesicles as well as in the
extracellular matrix. As well, in border areas of infarcted
myocardium, the more intense positivity for IL-1ra in
cardiomyocyte cytoplasms might correlate with an
increase in intracellular IL-1ra production. Actually, no
or negligible IL-1ra-positivity was shown by the
extracellular matrix in these areas, as for normal and
nonischemic myocardium.
The stronger IL-1ra positivity found in ischemic
areas could depend on increased intracellular IL-1ra
production, whereas the presence of reactivity in the
extracellular matrix could be ascribed to additional
production and release of secreted IL-1ra or abnormal
release of intracellular IL-1ra due to plasmamembrane
alteration in cardiomyocytes undergone coagulative
myocytolysis. 
The preferential deposition of colloidal gold at level
of collagen fibrils, elastin fibers and bundles of fibrillin
microfibrils is hardly explainable but represents an
intriguing issue. Direct interaction has been reported
between different cytokines and glycosaminoglycans. In
particular, concerning interleukin family members, the
finding of possible interaction of interleukin-2 with
heparan sulphate glycosaminoglycans was interpreted as
a mechanism by which this cytokine is retained near its
secretion sites (Najjam et al., 1997). Temptatively, it
could be speculated that IL-1ra might bind indirectly the
matrix fibrous components as above via
glycosaminoglycans. Since IL-1ra involvement in
myocardium is still far to be elucidated, such an
assumption could serve just as a starting point for future
investigation. 
Apart from possible involvement of the extracellular
matrix in ischemic areas, its reactivity with increasing
around altered cardiac cells can be correlated to IL-1ra
release by these cells, thereby seeming major cardiac
source of this cytokine. Such conclusion is corroborated
by the absence of significant IL-1ra immunostaining
observed for interstitial cells. 
Further, IL-1ra-immunopositive endothelial cells
were not detected in both normal and infarcted
myocardium. However, it cannot be excluded that blood
vessels may represent an additional source for IL-1ra
consistently with the finding that both intracellular IL-
1ra and secreted IL-1ra are naturally expressed in vivo
by ischemic coronary endothelial cells (Dewberry et al.,
2000). 
Thus, it might be assumed that in infarcted hearts
endothelial cells produce IL-1ra secondary to
atherosclerotic degeneration of ischemic blood vessels in
spite of the fact that endothelial cells did not show IL-
1ra positivity, because of its release as secreted isoform.
Moreover, it is possible that during infarction circulating
IL-1ra could diffuse into neighbouring myocardial tissue
via vessel wall endothelia. Such hypothesis is consistent
with the IL-1ra positivity exhibited by perivascular
extracellular matrix in ischemic areas of infarcted
myocardium. In the same areas, the detected plasma
reactivity could be ascribed to aspecific positivity;
however, in normal myocardium no reactivity was
detected for plasma and actual IL-1ra presence in plasma
and leucocytes was shown (Latini et al., 1994; Shibata et
al., 1997; Malyak et al., 1998; Arend and Guthridge,
2000; Patti et al., 2004). Likewise, vascular smooth
muscle cells did not show IL-1ra-positive staining in
both noninfarcted and infarcted myocardium. As was
hypothesized for endothelial cells, it is conceivable that
in ischemic areas of infarction vascular smooth muscle
cells can secrete IL-1ra not intracellularly detectable
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because of its possible release into the neighbouring
extracellular matrix, as suggested by the finding that IL-
1ra is present in supernatants of opportunely stimulated
vascular smooth muscle cell cultures (Di Febbo et al.,
1998).
Despite of the multiple putative IL-1ra sources
immunohistochemically revealed in infarcted
myocardium, it is obvious that critical conditions can
take place in which increased IL-1ra levels are not
sufficient to effectively block the biological effects of
the locally produced IL-1, as was observed in other
inflammatory diseases such as arthritis (Arend, 2002) or
atherosclerosis (Arend and Gabay, 2000). 
In conclusion, the present results strongly suggest
that a distinct IL-1ra distribution pattern exists in
myocardium advising the existence of intrinsic
production sites, and represent a starting point for further
investigation. Additional work has been undertaken to
confirm the identity of this protein and to gain more
detailed information on its involvement in normal and
infarcted myocardium.
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